Leverkusen, November 28, 2011 – Bayer HealthCare and Regeneron Pharmaceuticals, Inc. today announced that they have initiated a Phase III clinical trial evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept) in the neovascular form of age-related macular degeneration (wet AMD) in China. The new trial, named SIGHT, will include approximately 300 patients and will be the largest retinal trial ...
Leer Más


